HC Wainwright Reiterates “Buy” Rating for MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $35.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 234.13% from the company’s previous close.

A number of other analysts have also issued reports on the company. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings lowered MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Down 2.3%

NASDAQ INKT traded down $0.25 on Monday, reaching $10.48. The stock had a trading volume of 3,576 shares, compared to its average volume of 205,524. The firm has a market capitalization of $52.17 million, a price-to-earnings ratio of -3.69 and a beta of 0.47. MiNK Therapeutics has a 12-month low of $6.65 and a 12-month high of $76.00. The stock has a fifty day moving average price of $11.00 and a two-hundred day moving average price of $11.59.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Friday, May 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.20. Sell-side analysts forecast that MiNK Therapeutics will post -3.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.